Inicio | Foro | Revisión Bibliográfica | Micropapillary Cervical Adenocarcinoma. A Clinicopathologic Study of 44 Cases

Micropapillary Cervical Adenocarcinoma. A Clinicopathologic Study of 44 Cases

Isabel Alvarado-Cabrero, MD, PhD,* W. Glenn McCluggage, FRCPath,†
Rafael Estevez-Castro, MD,‡ Delia Pérez-Montiel, MD,§ Simona Stolnicu, MD, PhD,∥ Raji Ganesan, MD,¶ Josefa Vella, MBCh, MSc, FRCPath,¶ Rosario Castro, MD,#
Javier Canedo-Matute, MD,** Jessica Gomez-Cifuentes, MD,†† Vilma M. Rivas-Lemus, MD,‡‡
Kay J. Park, MD,§§ Robert A. Soslow, MD,§§ Esther Oliva, MD,∥∥ and Raquel Valencia-Cedillo, MD

Abstract: Micropapillary adenocarcinoma has been reported as an aggressive variant of adenocarcinoma in several organs, where it is associated with poor clinical outcome. This study reports the clin- icopathologic features and outcomes of cervical adenocarcinomas with a micropapillary component (micropapillary cervical ad- enocarcinomas); this represents the largest reported study of these neoplasms. The study comprised 44 cervical adenocarcinomas of usual (human papillomavirus–related)-type (84%), mucinous, not otherwise specified (4.5%), gastric-type (4.5%), endometrioid (4.5%), and adenosquamous carcinoma (2%). The micropapillary compo- nent comprised > 50% of the neoplasm in 34 cases (77%) (group 1), and 10% to 50% in 10 cases (23%) (group 2). Lymph node meta- stasis was present in 41 of 44 (93%) cases and typically the nodal tumor retained a prominent micropapillary morphology. Follow-up ranged from 7 to 123 months (mean, 65.9 mo). Seventeen of 44 (38.6%) patients had no evidence of disease on follow-up, 6/44 (13.6%) were alive with disease, and 21/44 (47.7%) died of disease. There were no survival differences between group 1 and group 2. On univariate analysis, lymph node metastasis (P = 0.0015), lympho- vascular space invasion (P = 0.002), parametrial involvement (P = 0.03), and depth of stromal invasion (P = 0.045) were related to tumor recurrence. On multivariate analysis, lymph node metastasis.

DESCARGAR ARTÍCULO

Check Also

Inmunohistoquímica en el diagnóstico de neoplasias ginecológicas. Una visión desde el punto de vista práctico para patólogos generales

Artículo de revisión
Patología 2019;57:1-16.
Diana Lizbeth Rodríguez-Orihuela,1 Isabel Alvarado-Cabrero,2 Jazmín De Anda-González1,2
1 Departamento de Anatomía Pato- lógica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México.
2 Departamento de Anatomía Pato- lógica, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México.

Deja una respuesta

Tu dirección de correo electrónico no será publicada.